

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Inc.

中國醫療集團有限公司

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

SUPPLEMENTAL ANNOUNCEMENT DISCLOSURES RELATING TO SHARE OPTION SCHEME AND CONTINUING CONNECTED TRANSACTION

With reference to the annual report of China Health Group Inc. (the “Company”) for the year ended 31 December 2025 published on 29 April 2026 (the “Annual Report”), the board of directors of the Company (the “Board”) issues this supplemental announcement to supplement certain information required under the GEM Listing Rules, which was inadvertently omitted during the preparation of the Annual Report. The Company has conducted a thorough internal review and strengthened its internal control and disclosure procedures to prevent the recurrence of similar inadvertent omissions in future corporate disclosures.

I. SHARE OPTION SCHEME

In accordance with Rule 23.07(2) of the GEM Listing Rules, the Company supplements and confirms the relevant information regarding its share option scheme as follows:

The share option scheme adopted by the Company on 30 June 2015 (the “Scheme”) expired on 30 June 2025.

As at the commencement of the financial year on 1 January 2025, the number of options available for grant under the mandate of the Scheme was 88,947,166.

No sub-limit for service providers was set by the Company under the Scheme.

II. CONTINUING CONNECTED TRANSACTION

In accordance with Rule 20.69(4) of the GEM Listing Rules, the Company supplements and confirms the details of the aforesaid continuing connected transaction as follows:

The service agreement entered into between the Company and Mr. Guo Xiao on 11 May 2022 (the “Agreement”) stipulates that the total transaction consideration shall be calculated based on the actual volume of services rendered from time to time.

The annual transaction caps applicable to the continuing connected transaction under the Agreement for the relevant financial years are set out below:

Year ended 31 December 2022: RMB50 million

Year ended 31 December 2023: RMB60 million

Year ended 31 December 2024: RMB72 million

The principal commercial terms of the Agreement are detailed as follows:

Service Scope: Provision of post-market research services, medical science services and medical market services

Payment Terms: A 180-day credit period is granted for payment settlement

Pricing Mechanism: The 42.7% service fee rate is determined with reference to the prevailing charging rates of independent third-party professional service providers in the industry, ensuring the pricing is made on an arm’s length, fair and reasonable commercial basis.

Save for the disclosures set out in this supplemental announcement, all other information and disclosures contained in the Annual Report remain unchanged, valid and in full force and effect. By Order of the Board

China Health Group Inc.
GUO Xia
Chairman

Hong Kong, 4 June 2026

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Mr. Raymond Guo; one non-executive Director, being Dr. ZHANG Li; and four independent non-executive Directors, being Dr. NI Binhui, Mr. WU Shuangsi, Dr. GUO Tong and Ms. LIU Na.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for 7 days from the date of its posting. This announcement will also be posted on the Company’s website at <http://www.chgi.net>.